2. Academic Validation
  3. Discovery of Quinazolinone Derivatives as Potent PARP1 Inhibitors

Discovery of Quinazolinone Derivatives as Potent PARP1 Inhibitors

  • ACS Med Chem Lett. 2026 Jan 13;17(2):282-283. doi: 10.1021/acsmedchemlett.5c00747.
Xin Zhou 1,  Steven H Liang 1 2
Affiliations

Affiliations

  • 1 Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
  • 2 Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States.
PMID: 41704379 DOI: 10.1021/acsmedchemlett.5c00747
Abstract

Poly-(ADP-ribose) polymerase 1 (PARP1) is the most abundant and well-characterized member of PARP family and plays a significant role in DNA damage detection and repair. Cancer cells with homogeneous recombination deficiency (HRD) depend on PARP1 mediated DNA repair for survival, which makes PARP1 as a potential Cancer treatment target. This patent highlights the synthesis and pharmaceutical composition of novel quinazolinone based PARP inhibitors for Cancer treatment.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-181265
    PARP1 Inhibitor